Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;39(2):416-425.
doi: 10.1007/s10637-020-01027-9. Epub 2020 Oct 30.

Notoginsenoside R1 counteracts mesenchymal stem cell-evoked oncogenesis and doxorubicin resistance in osteosarcoma cells by blocking IL-6 secretion-induced JAK2/STAT3 signaling

Minan Lu  1   2 , Kegong Xie  2 , Xianzhe Lu  2 , Lu Lu  2 , Yu Shi  2 , Yujin Tang  3   4
Affiliations

Notoginsenoside R1 counteracts mesenchymal stem cell-evoked oncogenesis and doxorubicin resistance in osteosarcoma cells by blocking IL-6 secretion-induced JAK2/STAT3 signaling

Minan Lu et al. Invest New Drugs. 2021 Apr.

Abstract

Tumor microenvironment is a critical participant in the initiation, progression and drug resistance of carcinomas, including osteosarcoma. Notoginsenoside R1 (NGR1) is a proverbial active ingredient of the traditional Chinese medicine Panax notoginseng (PN) and possess undeniable roles in several cancers. Nevertheless, its function in osteosarcoma and tumor microenvironment remains elusive. In the current study, exposure to NGR1 dose-dependently inhibited osteosarcoma cell viability and migration, and induced apoptosis. Furthermore, osteosarcoma cells that were incubated with conditioned medium (CM) from bone marrow mesenchymal stem cells (BMSCs) exhibited greater proliferation, migration capacity and MMP-2 and MMP-9 expression relative to control cells, which was reversed when BMSCs were treated with NGR1. Notably, administration with NGR1 antagonized CM-evoked doxorubicin resistance in osteosarcoma cells by decreasing cell viability and increasing cell apoptosis and caspase-3/9 activity. Mechanically, NGR1 suppressed IL-6 secretion from BMSCs, as well as the subsequent activation of the JAK2/STAT3 signaling in osteosarcoma cells. In addition, blocking the JAK2 pathway by its antagonist AG490 reversed CM-induced osteosarcoma cell proliferation, migration and doxorubicin resistance. Moreover, exogenous supplementation with IL-6 engendered not only the reactivation of the JAK2/STAT3 signaling but also muted NGR1-mediated efficacy against osteosarcoma cell malignancy and doxorubicin resistance. Collectively, NGR1 may directly restrain osteosarcoma cell growth and migration, or indirectly antagonize MSC-evoked malignancy and drug resistance by interdicting IL-6 secretion-evoked activation of the JAK2/STAT3 pathway. Consequently, the current study may highlight a promising therapeutic strategy against osteosarcoma by regulating tumor cells and the tumor microenvironment.

Keywords: Cell proliferation and migration; Drug resistance; MSCs; NGR1; Osteosarcoma; Tumor microenvironment.

PubMed Disclaimer

References

    1. Misaghi A, Goldin A, Awad M, Kulidjian AA (2018) Osteosarcoma: a comprehensive review. SICOT J 4:12. https://doi.org/10.1051/sicotj/2017028 - DOI - PubMed - PMC
    1. Anderson ME (2016) Update on Survival in Osteosarcoma. Orthop Clin North Am 47:283–292. https://doi.org/10.1016/j.ocl.2015.08.022 - DOI - PubMed
    1. Marina NM, Smeland S, Bielack SS et al (2016) Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol 17:1396–1408. https://doi.org/10.1016/S1470-2045(16)30214-5 - DOI - PubMed - PMC
    1. O'Kane GM, Cadoo KA, Walsh EM et al (2015) Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review. Clin Sarcoma Res 5:17. https://doi.org/10.1186/s13569-015-0032-0 - DOI - PubMed - PMC
    1. Zheng Y, Wang G, Chen R, Hua Y, Cai Z (2018) Mesenchymal stem cells in the osteosarcoma microenvironment: their biological properties, influence on tumor growth, and therapeutic implications. Stem Cell Res Ther 9:22. https://doi.org/10.1186/s13287-018-0780-x - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources